Bicycle Therapeutics (BCYC) shares fell more than 31% in recent Friday trading after the company said topline data from a phase 1/2 trial of zelenectide pevedotin combined with Merck's (MRK) pembrolizumab showed a 60% overall response rate in first-line metastatic urothelial cancer, in-line with existing therapies.
The company said it plans to report dose selection and topline data from a phase 2/3 trial in H2 2025.
Bicycle also said treatment with zelenectide pevedotin alone in breast cancer patients with Nectin4 gene amplification showed "enhanced anti-tumor activity."
The company said it will advance its development strategy, including phase 1/2 trials in breast, lung, and multi-tumor cancers, starting in 2025.
Price: 13.77, Change: -6.35, Percent Change: -31.55
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.